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AbstrAct
Olfactory neuroblastoma (ON) is a rare tumour of the olfactory neuroepithelium that is characterized by a pattern 
of slow growth and local recurrences. Combination of surgery and radiotherapy, with or without chemotherapy, is 
considered to be the standard of care for primary site disease. Recent literature supports  the view that endoscopic 
resection followed by adjuvant radiotherapy correlates with better outcome. In this short communication, we present 
a case report of olfactory neuroblastoma arising in the right nasal sinus in a 34-year-old male. This patient was treated 
with endoscopic resection and external beam radiotherapy to the right nasal sinus with intensity-modulated radia-
tion therapy (IMRT) technique. After 2 years follow-up, the patient is free of tumour without any late effect related to 
therapies. We believe that, in such patients, a treatment strategy including endoscopic resection followed by adjuvant 
radiotherapy may be effective and feasible and should be considered the gold standard of care.
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introDuction
Olfactory neuroblastoma (ON) originates from the  olfac-
tory epithelium. Unilateral nasal obstruction and epistaxis 
are the most common symptoms. Furthermore, headache, 
sinus pain, excessive lacrimation, rhinorrhea, anosmia and 
changes in vision may occur. Treatment modalities for 
ON are surgery combined with radiotherapy (RT) and/or 
chemotherapy.1 In this short communication, we report the 
case of a patient with a mass in the right nasal cavity who 
was treated by endoscopic resection and adjuvant RT.
cAse report
A 34-year-old male was referred to our hospital where he 
presented a 6-month history of unilateral nasal obstruction 
and frontal headache. Endoscopic examination showed 
a polypoid mass in the right nasal cavity and permitted 
biopsy of the lesion. Histological findings documented an 
olfactory neuroblastoma of Grade II according to Hyams 
grading system. MRI was performed, revealing a well- 
circumscribed lesion in the right nasal sinus, hypointense 
on T1 weighted and hyperintense on T2 weighted 
sequences (Figure  1). This disease presentation corre-
sponded to Kadish stage B. After discussion in the multi-
disciplinary tumour board, a bimodality therapeutic 
approach consisting of endoscopic resection followed 
by adjuvant radiotherapy  (RT) was chosen. The patient 
was treated with a wide tumour excision by nasal endo-
scopic surgery, and postoperative pathology confirmed 
a moderate grade ON. 20  days later, the patient was 
planned to receive adjuvant external beam RT, delivered 
with a step and shoot (S  &S) intensity-modulated radi-
ation therapy (IMRT) technique. After proper immo-
bilization (flat headboard and thermoplastic mask), 
a planning CT  simulation with 3 mm slice thickness 
was performed. Target volume and organs at risk were 
contoured using the treatment planning system Master-
plan, Oncentra (Nucleotron, Crawley, UK). A semi-auto-
matic rigid registration between planning CT scan and 
diagnostic MRI images was performed to better define 
the clinical target volume (CTV) that included the preop-
erative tumour bed. A 5-mm isotropic margin was added 
to the CTV to obtain the planning target volume (PTV) 
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Figure 1. Hypointense T1 weighted (a), hyperintense T2 weighted (b) and coronal (c) preoperative MRI images
Figure 2. Axial (a, b), coronal (c) and sagittal (d) views of 
target volumes: inner lines correspond to clinical target 
volume, whereas outer lines represent planning target volume
Figure 3. Dose distribution in axial (a, b), coronal (c) and 
sagittal (d) CT planning slices: the inner line corresponds to 
the  planning target volume, whereas the other lines going 
outwards represent 95, 80 and 50% isodoses, respectively
(Figure  2). Beam geometry in IMRT plan consisted of five 
coplanar 6 MV fields. The prescribed dose was 60 Gy in 30 
fractions (2 Gy daily) defined as the mean dose planned to the 
PTV  with 95% of the PTV receiving ≥95% of the prescribed 
dose. Dose–volume histogram   was calculated for the IMRT 
plan for the following volumes: PTVs, spinal cord, brainstem, 
optic chiasm, eyes, optic nerves and lens. The dose–volume 
constraints were satisfied: 0.03 cc of the optic chiasm, optic 
nerves, eyes and brainstem should receive <54 Gy, spinal cord 
45 Gy and lens 6 Gy. The dose distribution is shown in Figure 3. 
Radiation treatment was well tolerated with Grade 1 skin acute 
toxicity according to Radiation Therapy Oncology Group scale 
and nasal obstruction. No treatment interruption occurred. 
The patient is still under regular follow-up based on MRI and 
nasal endoscopy; after 2 years of observation, he continues to 
be free from disease without any late complications of therapy.
Discussion
ON is a rare malignant tumour of the nasal cavity and it arises 
from the olfactory neuroepithelium located in the nasal septum.2 
Commonly, this tumour causes unilateral nasal obstruction and 
epistaxis. Minor manifestations are anosmia, headache, sinus 
pain, rhinorrhea and epiphora. In the present case, the patient 
showed unilateral nasal obstruction and frontal headache. Clin-
ically, ON is staged using the Kadish system that is based on the 
spread of the tumour.3 According to this system, stage A corre-
sponds to tumours confined to the nasal cavity, stage B includes 
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lesions involving also the paranasal sinuses, whereas stage C 
presents masses that extent beyond the nasal cavity and para-
nasal sinuses.3 MRI scan is essential to study disease extension 
and usually reveals a tumour mass presenting a low-intensity 
signal in T1 weighted images and an iso- or high-intensity signal 
in T2 weighted images. A key issue consists in  early histological 
diagnosis of ON through endoscopic biopsy. Many studies tend 
to divide ON into low-grade and high-grade lesions according to 
Hyams classification identifying two distinct entities. Malouf et 
al4 showed that patients with high-grade ON had larger tumours, 
frequent lymph node involvement and more often leptomenin-
geal metastasis compared to low-grade ON. In our case, MRI 
showed a Kadish stage B ON and endoscopic biopsy revealed a 
low-grade ON.
The available literature indicates that a combination of surgery 
and RT is the best treatment approach.5 Although craniofacial 
resection is considered the gold standard surgical treatment, 
some recent reports suggest  treating ON with minimally 
invasive surgery. In fact, endoscopic approaches present some 
advantages such as shorter surgical time and hospitalization 
and a better quality of life.6 Table 1 reports studies including 
treatment characteristics and outcome for olfactory neuro-
blastoma. Some reports showed that the addition of postoper-
ative radiation to surgery significantly improves local control 
rates. In the study of Dulguerov and Calcaterra7 local control 
was 86% with combined treatment and 17% with surgery 
alone. Morita et al6 reported a local recurrence rate of 55% 
in patients who  underwent total resection alone versus 19% 
in patients treated with total resection and adjuvant RT. Chao 
et al12 recommended a combined modality treatment in all 
Kadish stages of disease. In the study of Diaz et al3 10-year 
disease-specific survival rate was 100% in patients with Kadish 
A/B stage who  underwent  surgery and postoperative  RT. 
More recently, Ow et al23 retrospectively reviewed 70 patients 
affected by ON treated at the MD Anderson Cancer Center 
showing a median disease-specific survival of 87.9 months 
for patients who received surgery alone and 218.5 months for 
those underwent  surgery and postoperative RT (p = 0.047). 
They concluded that survival is considerably better when 
surgical resection is followed by adjuvant RT. In the study of 
Mori et al26 multimodal therapy including RT with precise 
treatment planning based on CT simulation achieved an excel-
lent local control rate, and the 5-year overall survival (OS) and 
relapse-free survival (RFS) rates were estimated at 88 and 74%, 
respectively.
With regard to the RT technique, when the tumour involves 
adjacent structures such as the  infraorbital canal or optic 
nerve, IMRT is recommended because it better preserves 
closer structures.23, 26, 27 In our clinical case, a combined 
strategy consisting of endoscopic surgery and adjuvant IMRT 
was chosen.
The radiation dose greatly varies among the studies in the liter-
ature. In the postoperative setting, mean radiation doses of 56.9 
Gy (range 50.0–67.2 Gy) and 54.57 Gy (range 45–60 Gy) were 
reported by Diaz et al3 and Bachar et al16 respectively. More 
recently, Mori et al used 50 to 66 Gy as postoperative RT, 40 Gy 
as preoperative RT and 54 to 66 Gy in the setting of sequential 
chemoradiation therapy. In the absence of randomized studies, 
Lapierre et al27 recommended the doses currently used in the 
treatment of  other sinonasal tumours, between 60 and 70 Gy 
in 30–35 fractions based on tumour site, pathological charac-
teristics and quality of surgical resection. In our clinical case, 
we delivered a total dose of 60 Gy in 30 fractions (2 Gy daily) 
because this is the schedule we used in the postoperative setting 
for sinonasal tumours and because the patient underwent a 
wide tumour excision by nasal endoscopic surgery with negative 
margins.
In patients affected with ON, it is difficult to decide the 
optimal RT treatment volume. Radiation fields should include 
the tumour bed and potential sites of local spread. Klepin 
et al28 suggested that the treatment volumes covered the entire 
nasal fossa, the maxillary sinuses with an extension into the 
ethmoid, the sphenoid sinus and the anterior cranial fossa to 
control brain invasion. The role of elective nodal irradiation 
(ENI) in ON is still controversial; the study of Elkon et al29 
reported a neck nodal failure rate of 10% suggesting that ENI 
was not necessary in node-negative patients. More recently, 
other studies reported regional failure rates of 23.4 and 27% 
suggesting that ENI should be considered when the primary 
disease is locally advanced or when regional neck node is posi-
tive at diagnosis.30, 31 In 2011, Noh et al32  concluded that ENI 
for ON plays a limited role in preventing cervical nodal failure 
and that omitting ENI may be an option in patients affected by 
advanced disease treated with a combination of RT and chemo-
therapy. In the study of Lapierre et al27 none of the patients 
received prophylactic cervical irradiation and there were two 
recurrences (28%) in the neck nodes. Relapses were treated by 
surgery in one patient and by the combination of surgery and 
adjuvant RT in the other patient. In a recent large cohort study, 
a significant improvement in the 5-year local control rate with 
prophylactic nodal irradiation was demonstrated (75 vs 98% 
without and with ENI, respectively, p = 0.005). The authors 
concluded that ENI should be recommended as a part of 
the initial treatment strategy for patients staged with modified 
Kadish B/C.33
In our clinical case, after discussing with the patient about the 
literature data regarding the prophylactic cervical irradiation, 
the pros and cons and the side effects, we opted for an RT volume 
that included the tumour bed and we decided not to perform 
ENI owing to the limited Kadish B stage, radical surgery, absence 
of clinically and radiologically positive nodes and the possibility 
of treatment at the time of recurrence.
Furthermore, in addition to surgery and RT, chemotherapy 
may offer improvement in local control and reduction in the 
frequency of distant metastasis, especially in patients with unre-
sectable tumours or in case of advanced disease and recurrent 
and metastatic lesions.34
conclusion
In our opinion, this case report shows that a combined modality 
approach with minimally invasive surgery and postoperative 
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